A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
Status:
Completed
Trial end date:
2019-01-29
Target enrollment:
Participant gender:
Summary
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy
of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases
(CKD): CKD associated with type 1 diabetes (T1D), IgA nephropathy (IgAN), focal segmental
glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD). Patients
will be enrolled in disease specific cohorts within the trial, and effectiveness of
bardoxolone methyl in treating CKD will be assessed separately by cohort for each rare CKD.
All patients in the study will follow the same visit and assessment schedule. Following
randomization on Day 1, patients will be scheduled to be assessed during treatment at Weeks
1, 2, 4, 6, 8, and 12, and by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients
will also be scheduled to be assessed at an in-person follow-up visit at Week 16, four weeks
after the end of treatment.